LRRK2 and Parkinson disease: Carriers of the kinase-activating LRRK2 G2019S variant have been reported to have elevated urine BMP levels, and LRRK2 kinase inhibition resulted in a dose-dependent reduction in urine BMP levels in healthy volunteers and PD patients [14, 32].